Tests to Chapter 21,22

1. Only one drug stimulates leukopoiesis:

A. Pentoxilum
B. Methotrexate
C. Actinomycin
D. Prednisolone
E. Rituxan7

2. The main effect of cyanocobalamin include:

A. The improvement of leucocytes forming

B. The transformation of megaloblastic erythropoiesis into normoblastic one
C. An increase in the amount of thrombocytes
D. An antiplatelet action
E. Reducing of the neurological symptoms of megaloblastic anemia.

3. All the listed is correct, except:

A. Ferrous sulfate is used to form hemoglobin in the erythrocytes

B. Ferrous sulfate is used to form myoglobin in muscles
C. Ferrous sulfate is used to form some enzymes (cytochrome oxidase and others)
D. Fe++ absorption is stimulated by vitamin C
E. Fe++ absorption is inhibited by glucose.

4. Antidote of acute poisoning with ferrous compounds is:

A.Coamid
B. Epoetin beta
C. Desferal
D.Folic acid
E. Imiphos

5. Folic acid:

A. Takes part in the synthesis of purine and pyrimidine nucleotides, amino

acids and proteins
B. Is a lipid-soluble vitamin
C. Is taken intramuscularly
1
 D. Is not used together with cyanocobalamin
E. Is contraindicated in chronic gastroenteritis.

6. Only one drug inhibits leukopoiesis:

A. Ferkoven
B. Pentoxilum
C. Methyluracil
D. 6-Mercaptopurine
E. Molgastim

7. Only one drug inhibits erhythropoiesis:

A. Imiphos
B. Molgastim
C. Methotrexate
D. Lenogastim
E. Rituxan

8. A patient has the pale skin and mucous membranes, weakness, tachycardia.
The total amount of red blood cells is 3,5 x 1012/L. Colored index is 0,76. It
is known, that he has gastritis with lower acidity of gastric juice. Point out
a correct diagnosis and the basic preparation for the therapy:

A. Megaloblastic anemia, cyanocobalamin

B. Hemolytic anemia, prednisolone
C. Anemia due to chronic renal failure, epoetin
D. Hemochromatosis, desferal
E. Iron-deficient anemia, ferrum-lek.

9. Drug for the prevention of bleeding is:

A. Vikasol
B. Thrombin
C. Heparin
D. Streptokinase
E. Contrycal.

10. All the listed is correct, except:

2
 A. Aminocaproic acid is an indirect-acting anticoagulant
B. Aminocaproic acid is a direct-acting anticoagulant
C. Aminocaproic acid is an inhibitor of fibrinolysis
D. Aminocaproic acid is not metabolized
E. Aminocaproic acid inhibits proteolytic enzymes

11. All the listed is correct, except:

A. Etamsylate promotes angioprotective and proaggregant action

B. Etamsylate stimulates thrombocytopoiesis
C. Etamsylate has a hemostatic action
D. Etamsylate increases edema
E. Etamsylate is used for prophylaxis and control of capillary bleeding

12. Therapeutic uses of antiplatelet drugs include all listed, exept:

A. Acute thrombosis
B. The prevention of secondary thrombosis
C. Use of prosthetic heart valves
D. Arteriovenous shunt for hemodialysis
E. Thrombophlebitis

13. Heparin is an anticoagulant which:

A. Is effective orally

B. Binds to antithrombin III

C. Is not metabolized

D. Inhibits the release of lipoprotein lipase from the endothelial cells

E. Has a positive charge.

14. Direct-acting coagulants include all listed, except:

A. Thrombin
B. Calcium chloride
C. Hemostatic sponge
D. Menadione

3
 E. Calcium gluconate

15. Fibrinogen is:

A. Is an active compound of the blood coagulation system

B. Is a non-active compound of the blood coagulation system
C. Is a recombinant activated factor VII
D. Is indirect-acting coagulant
E. Is administered orally

16. Indirect-acting (are active only in vivo) anticoalulants:

A. Fraxiparine
B. Enoxaparin
C. Fondaparinux
D. Warfarin
E. Rivaroxaban

17. The first available orally active direct factor Xa inhibitor is:

A) Fraxiparine
B) Enoxaparin
C) Fondaparinux
D) Warfarin
E) Rivaroxaban

18. Indications for ethyl biscoumacetate (neodicumarinum)

A) Hemodialysis or blood transfusion

B) Myocardial infarction
C) Hemorrhagic diathesis
D) A syndrome of disseminated intravascular blood coagulation
E) Atherosclerosis

19. A patient with acute myocardial infarction was treated with intravenous
infusion of streptokinase. What is the goal of this drug administration?:

A. To transform plasminogen into plasmin

B. To cause the lysis of thrombus directly
4
 C. To prevent further thrombosis
D. To prevent platelets activation
E. To decrease the area of necrosis
20. Diosmin:

A. Decrease lymphatic drainage

B. Increase lymphatic drainage
C. Doesn’t influence on lymphatic drainage
D. Doesn’t influence on venous tone
E. Doesn’t influence on capillary permeability